Clear Search sequence regions


  • acetate (9)
  • CCN1 (1)
  • CCN2 (1)
  • CPA3 (1)
  • endometrium (5)
  • female (1)
  • fibroids (2)
  • human (2)
  • livers (1)
  • mast cell (2)
  • myometrium (4)
  • norpregnadienes (2)
  • patients (2)
  • steroids (1)
  • TPSAB1 (1)
  • TPSB2 (1)
  • women (1)
  • Sizes of these terms reflect their relevance to your search.

    The aim of this study was to assess the molecular effect of ulipristal acetate (UPA) on gene expression in myometrium and endometrium of patients with symptomatic fibroids. Tissues isolated from four women treated preoperatively with UPA (5 mg) were compared to those from untreated controls using NanoString platform to assess the expression of 75 candidate genes modulated by UPA and ovarian steroids. Deregulated genes were then validated by real-time PCR. In myometrium, UPA exerted an antagonistic effect similar to that observed in fibroids. In UPA-treated endometrium, six genes were identified as highly and significantly upregulated, including matricellular genes CCN1 (54-fold, P = 0.0018) and CCN2 (11-fold, P = 0.00044), Krüppel-like factor 4 (>3-fold, P = 0.0036), and mast cell markers including tryptases TPSAB1/TPSB2 (31-fold, P = 0.023) and carboxypeptidase A (CPA3, 17-fold, P = 0.05). In endometrium, UPA induced the expression of genes involved in fibrogenesis and mast cell function-some of them being widely involved in hepatic injury, which could explain the marked fibrosis and inflammatory cell infiltration observed in explanted livers from patients under UPA treatment.

    Citation

    Ana Salas, Paula Vázquez, Aixa R Bello, Delia Báez, Teresa A Almeida. Dual agonist-antagonist effect of ulipristal acetate in human endometrium and myometrium. Expert review of molecular diagnostics. 2021 Aug;21(8):851-857

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 34110938

    View Full Text